@article {TSUCHIE2095, author = {HIROYUKI TSUCHIE and MAKOTO EMORI and NAOHISA MIYAKOSHI and HIROYUKI NAGASAWA and KYOJI OKADA and HIROSHI NANJYO and YASUTAKA MURAHASHI and EMI MIZUSHIMA and JUNYA SHIMIZU and TOSHIHIKO YAMASHITA and YOICHI SHIMADA}, title = {Prognostic Impact of CD44 Expression in Patients With Myxofibrosarcoma}, volume = {33}, number = {6}, pages = {2095--2102}, year = {2019}, doi = {10.21873/invivo.11709}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Abnormal expression of CD44 may promote cancer invasion. However, a limited number of studies have investigated the expression of CD44 in soft tissue sarcoma such as myxofibrosarcoma. We evaluated the relationship between expression of the standard form of CD44 (CD44s) and the clinical course of myxofibrosarcoma. Materials and Methods: Forty-four myxofibrosarcoma patients were retrospectively enrolled. Patient information including the proportion of CD44s-positive cells was collected, and multivariate analyses were conducted to determine the relationship between CD44s expression and clinicopathological factors. Results: Although CD44s did not affect prognosis, multivariate analysis indicated that high expression of CD44s predicted poor event-free survival (p=0.004) and local recurrence (p=0.049). CD44s expression was not associated with the occurrence of distant metastasis but was significantly higher in those with lung metastasis (p=0.044). Conclusion: Increased expression of CD44s predicted poor event-free survival and local recurrence and was observed in myxofibrosarcoma patients with lung metastasis.}, issn = {0258-851X}, URL = {https://iv.iiarjournals.org/content/33/6/2095}, eprint = {https://iv.iiarjournals.org/content/33/6/2095.full.pdf}, journal = {In Vivo} }